{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:42:37Z","timestamp":1791243757706,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Prostaglandins &amp; Other Lipid Mediators"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.prostaglandins.2011.03.001","type":"journal-article","created":{"date-parts":[[2011,3,11]],"date-time":"2011-03-11T11:45:42Z","timestamp":1299843942000},"page":"124-132","source":"Crossref","is-referenced-by-count":22,"title":["BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase"],"prefix":"10.1016","volume":"94","author":[{"given":"C\u00e9line","family":"Cherdon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Rolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Ooms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"de Leval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Drion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Michiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Pirotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Masereel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natzi","family":"Sakalihassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Olivier","family":"Defraigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Dogn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.prostaglandins.2011.03.001_bib0005","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.biocel.2009.06.002","article-title":"Atherosclerotic plaque development","volume":"41","author":"Bui","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"issue":"17","key":"10.1016\/j.prostaglandins.2011.03.001_bib0010","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJM198404263101701","article-title":"Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation","volume":"310","author":"FitzGerald","year":"1984","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.prostaglandins.2011.03.001_bib0015","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/01.CIR.102.8.840","article-title":"Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis","volume":"102","author":"Belton","year":"2000","journal-title":"Circulation"},{"issue":"6310","key":"10.1016\/j.prostaglandins.2011.03.001_bib0020","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/349617a0","article-title":"Cloning and expression of cDNA for a human thromboxane A2 receptor","volume":"349","author":"Hirata","year":"1991","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.prostaglandins.2011.03.001_bib0025","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1211\/0022357011775992","article-title":"Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor","volume":"53","author":"Dogne","year":"2001","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"10.1016\/j.prostaglandins.2011.03.001_bib0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1054\/plef.2001.0290","article-title":"Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles","volume":"65","author":"Rolin","year":"2001","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"1\u20132","key":"10.1016\/j.prostaglandins.2011.03.001_bib0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.prostaglandins.2007.03.002","article-title":"BM-520, an original TXA2 modulator, inhibits the action of thromboxane A2 and 8-iso-prostaglandin F2alphain vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents","volume":"84","author":"Rolin","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"1","key":"10.1016\/j.prostaglandins.2011.03.001_bib0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1124\/jpet.102.046607","article-title":"BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis","volume":"306","author":"Rolin","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.prostaglandins.2011.03.001_bib0045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1124\/jpet.104.079301","article-title":"In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N\u2032-[2-(4\u2032-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist","volume":"313","author":"Hanson","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.prostaglandins.2011.03.001_bib0050","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1096\/fj.03-1364fje","article-title":"The isoprostane 8-iso-PGF2alpha suppresses monocyte adhesion to human microvascular endothelial cells via two independent mechanisms","volume":"19","author":"Kumar","year":"2005","journal-title":"FASEB J"},{"issue":"18","key":"10.1016\/j.prostaglandins.2011.03.001_bib0055","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1161\/CIRCULATIONAHA105.562223","article-title":"Involvement of thromboxane receptor in the proatherogenic effect of isoprostane F2alpha-III: evidence from apolipoprotein E- and LDL receptor-deficient mice","volume":"112","author":"Tang","year":"2005","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.prostaglandins.2011.03.001_bib0060","doi-asserted-by":"crossref","first-page":"9383","DOI":"10.1073\/pnas.87.23.9383","article-title":"A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism","volume":"87","author":"Morrow","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.prostaglandins.2011.03.001_bib0065","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1124\/jpet.103.063610","volume":"309","author":"Dogne","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1016\/j.prostaglandins.2011.03.001_bib0070","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.ATV.20.7.1724","article-title":"The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis","volume":"20","author":"Cayatte","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.prostaglandins.2011.03.001_bib0075","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood-2006-08-044990","article-title":"Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice","volume":"109","author":"Cyrus","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.prostaglandins.2011.03.001_bib0080","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1172\/JCI107470","article-title":"Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria","volume":"52","author":"Jaffe","year":"1973","journal-title":"J Clin Invest"},{"issue":"5567","key":"10.1016\/j.prostaglandins.2011.03.001_bib0085","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1126\/science.1068711","article-title":"Role of prostacyclin in the cardiovascular response to thromboxane A2","volume":"296","author":"Cheng","year":"2002","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.prostaglandins.2011.03.001_bib0090","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1182\/blood.V96.12.3823","article-title":"Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis","volume":"96","author":"Pratico","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.prostaglandins.2011.03.001_bib0095","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1172\/JCI200421446","article-title":"Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice","volume":"114","author":"Kobayashi","year":"2004","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.prostaglandins.2011.03.001_bib0100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/01.ATV.14.1.141","article-title":"Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression","volume":"14","author":"Reddick","year":"1994","journal-title":"Arterioscler Thromb"},{"issue":"3","key":"10.1016\/j.prostaglandins.2011.03.001_bib0105","first-page":"503","article-title":"Mouse models of experimental atherosclerosis","volume":"55","author":"Jawien","year":"2004","journal-title":"J Physiol Pharmacol"},{"issue":"10","key":"10.1016\/j.prostaglandins.2011.03.001_bib0110","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1073\/pnas.91.10.4431","article-title":"Brown MS. The two-receptor model of lipoprotein clearance: tests of the hypothesis in \u201cknockout\u201d mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins","volume":"91","author":"Ishibashi","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5262","key":"10.1016\/j.prostaglandins.2011.03.001_bib0115","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1126\/science.272.5262.685","article-title":"Mouse models of atherosclerosis","volume":"272","author":"Breslow","year":"1996","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.prostaglandins.2011.03.001_bib0120","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1021\/np9905261","article-title":"Chapecoderins A-C, new labdane-derived diterpenoids from Echinodorus macrophyllus","volume":"63","author":"Kobayashi","year":"2000","journal-title":"J Nat Prod"},{"issue":"3\u20134","key":"10.1016\/j.prostaglandins.2011.03.001_bib0125","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1050-1738(01)00099-8","article-title":"Lipid peroxidation in mouse models of atherosclerosis","volume":"11","author":"Pratico","year":"2001","journal-title":"Trends Cardiovasc Med"},{"issue":"25","key":"10.1016\/j.prostaglandins.2011.03.001_bib0130","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1161\/01.CIR.98.25.2822","article-title":"Increased formation of distinct F2 isoprostanes in hypercholesterolemia","volume":"98","author":"Reilly","year":"1998","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.prostaglandins.2011.03.001_bib0135","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0021-9150(03)00097-2","article-title":"Adhesion molecules and atherosclerosis","volume":"170","author":"Blankenberg","year":"2003","journal-title":"Atherosclerosis"},{"issue":"1\u20132","key":"10.1016\/j.prostaglandins.2011.03.001_bib0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cca.2005.12.030","article-title":"Circulating markers of endothelial function in cardiovascular disease","volume":"368","author":"Constans","year":"2006","journal-title":"Clin Chim Acta"},{"issue":"5","key":"10.1016\/j.prostaglandins.2011.03.001_bib0145","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1161\/01.ATV.18.5.842","article-title":"Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse","volume":"18","author":"Nakashima","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"10.1016\/j.prostaglandins.2011.03.001_bib0150","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1161\/01.CIR.0000027816.54430.96","article-title":"Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice","volume":"106","author":"Cyrus","year":"2002","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.prostaglandins.2011.03.001_bib0155","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1046\/j.1365-2249.1998.00614.x","article-title":"Stimulation with thromboxane A2 (TXA2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells","volume":"112","author":"Ishizuka","year":"1998","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"10.1016\/j.prostaglandins.2011.03.001_bib0160","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1096\/fj.00-0498fje","article-title":"The isoprostane 8-iso-PGF(2alpha) stimulates endothelial cells to bind monocytes: differences from thromboxane-mediated endothelial activation","volume":"15","author":"Leitinger","year":"2001","journal-title":"FASEB J"},{"issue":"6","key":"10.1016\/j.prostaglandins.2011.03.001_bib0165","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1043-2760(01)00411-8","article-title":"The isoprostanes in biology and medicine","volume":"12","author":"Pratico","year":"2001","journal-title":"Trends Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.prostaglandins.2011.03.001_bib0170","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00041433-199810000-00008","article-title":"Oxidized phospholipids and isoprostanes in atherosclerosis","volume":"9","author":"Witztum","year":"1998","journal-title":"Curr Opin Lipidol"}],"container-title":["Prostaglandins &amp; Other Lipid Mediators"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882311000244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882311000244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T08:04:36Z","timestamp":1592381076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098882311000244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":34,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S1098882311000244"],"URL":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2011.03.001","relation":{},"ISSN":["1098-8823"],"issn-type":[{"value":"1098-8823","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}